Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Apheresis

I M Nilsson1, C Freiburghaus

  • 1Department for Coagulation Disorders, University of Lund, Sweden.

Advances in Experimental Medicine and Biology
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Extracorporeal immunoadsorption effectively removes inhibitors in hemophilia patients, enabling factor replacement therapy. This method offers a safe and efficient alternative for managing bleeding and surgical procedures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduction of ultraviolet light-induced DNA damage in human colon cancer cells treated with a lactoferrin-derived peptide.

Journal of dairy science·2012
Same author

Identification of ubiquitin in bovine milk and its growth inhibitory effects on human cancer cell lines.

Journal of dairy science·2010
Same author

Lactoferricin treatment decreases the rate of cell proliferation of a human colon cancer cell line.

Journal of dairy science·2009
Same author

Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity.

The Journal of infectious diseases·1999
Same author

Commentary to Erik von Willebrand's original paper from 1926 'Hereditär pseudohemofili'.

Haemophilia : the official journal of the World Federation of Hemophilia·1999
Same author

Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis.

Nature medicine·1999

Area of Science:

  • Hematology
  • Immunology
  • Biotechnology

Background:

  • Hemophilia patients with inhibitors face challenges in treatment effectiveness.
  • Conventional methods like plasma exchange have limitations and risks.

Purpose of the Study:

  • To present two novel extracorporeal immunoadsorption methods for removing inhibitors against factor VIII (F.VIII) and factor IX (F.IX).
  • To evaluate the efficacy and safety of these methods in hemophilia patients.

Main Methods:

  • Group-specific elimination using protein A Sepharose columns for antibody adsorption from plasma.
  • Specific elimination using immobilized coagulation factor (F.IX) for direct whole blood antibody adsorption.

Main Results:

  • Successful removal of high-titer inhibitors in hemophilia and acquired hemophilia patients, enabling factor replacement therapy.

Related Experiment Videos

  • Treatment was well-tolerated with no observed activation of coagulation, fibrinolytic, or complement systems.
  • Specific F.IX antibody removal from whole blood was achieved without side effects.

    • Conclusions:

    • Extracorporeal immunoadsorption is a safe and effective strategy for managing hemophilia patients with inhibitors.
    • These methods facilitate conventional replacement therapy for bleeding control and surgical cover.
    • Future applications may include immobilized F.VIII for F.VIII antibody removal.